Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of two corticosteroid medications, dexamethasone and prednisone, both of which are synthetic glucocorticoids used to treat various inflammatory and autoimmune conditions. Dexamethasone is a long-acting corticosteroid with a half-life of 36-72 hours, while prednisone is an intermediate-acting corticosteroid with a half-life of 3-4 hours. Dexamethasone is approximately 7 times more potent than prednisone (1mg of dexamethasone is equivalent to about 7mg of prednisone)[5][9]. Research has shown that combining prednisolone (the active form of prednisone) with low-dose dexamethasone (1/50 w/w) can dramatically increase anti-leukemic activity compared to prednisolone alone in treating childhood acute lymphoblastic leukemia[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + prednisone.